
## Melissa P Delbello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8060855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brain morphometric features predict medication response in youth with bipolar disorder: a prospective randomized clinical trial. Psychological Medicine, 2023, 53, 4083-4093.	4.5	3
2	Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 243-254.	0.5	12
3	A preliminary study of the effects of mindfulnessâ€based cognitive therapy on structural brain networks in moodâ€dysregulated youth with a familial risk for bipolar disorder. Microbial Biotechnology, 2022, 16, 1011-1019.	1.7	4
4	Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 1106-1118.e2.	0.5	8
5	Pretreatment Alterations and Acute Medication Treatment Effects on Brain Task–Related Functional Connectivity in Youth With Bipolar Disorder: A Neuroimaging Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 1023-1033.	0.5	6
6	Structural connectivity associated with familial risk for mental illness: A metaâ€analysis of diffusion tensor imaging studies in relatives of patients with severe mental disorders. Human Brain Mapping, 2022, 43, 2936-2950.	3.6	6
7	A customized adherence enhancement program for adolescents and young adults with suboptimal adherence and bipolar disorder: Trial design and methodological report. Contemporary Clinical Trials, 2022, 115, 106729.	1.8	6
8	Editorial: Assessing the Predictive Characteristics of Second-Generation Antipsychotic Early Nonresponse in Youth With First-Episode Psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, , .	0.5	0
9	Changes in the structural brain connectome over the course of a nonrandomized clinical trial for acute mania. Neuropsychopharmacology, 2022, , .	5.4	2
10	A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder. Journal of Personalized Medicine, 2022, 12, 1006.	2.5	2
11	Symptom Profiles, But Not Prefrontal Neurochemistry, Differentiate ADHD Youth With and Without a Family History of Bipolar I Disorder. Journal of Attention Disorders, 2022, 26, 1762-1773.	2.6	3
12	Variation in rostral anterior cingulate functional connectivity with amygdala and caudate during first manic episode distinguish bipolar young adults who do not remit following treatment. Bipolar Disorders, 2021, 23, 500-508.	1.9	10
13	Nâ€acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and metaâ€analysis of randomized controlled trials. Bipolar Disorders, 2021, 23, 707-714.	1.9	15
14	CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 56-62.	1.3	9
15	Association between poor tolerability of antidepressant treatment and brain functional activation in youth at risk for bipolar disorder. Revista Brasileira De Psiquiatria, 2021, 43, 70-74.	1.7	5
16	Changes in the brain structural connectome after a prospective randomized clinical trial of lithium and quetiapine treatment in youth with bipolar disorder. Neuropsychopharmacology, 2021, 46, 1315-1323.	5.4	20
17	N â€acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: A pilot study. Microbial Biotechnology, 2021, , .	1.7	3
18	Network-level functional topological changes after mindfulness-based cognitive therapy in mood dysregulated adolescents at familial risk for bipolar disorder: a pilot study. BMC Psychiatry, 2021, 21, 213.	2.6	12

#	Article	IF	CITATIONS
19	Fish oil supplementation alters emotionâ€generated corticolimbic functional connectivity in depressed adolescents at highâ€risk for bipolar I disorder: A 12â€week placeboâ€controlled fMRI trial. Bipolar Disorders, 2021, , .	1.9	5
20	Irritability, Anger, and Aggression in the Context of Pediatric Bipolar Disorder. Child and Adolescent Psychiatric Clinics of North America, 2021, 30, 561-571.	1.9	2
21	Combining Deep Learning and Graph-Theoretic Brain Features to Detect Posttraumatic Stress Disorder at the Individual Level. Diagnostics, 2021, 11, 1416.	2.6	6
22	A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 485-493.	1.3	16
23	Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis. Journal of Affective Disorders, 2021, 292, 319-327.	4.1	6
24	Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 494-503.	1.3	3
25	Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 1309-1318.	0.5	14
26	Individual prediction of symptomatic converters in youth offspring of bipolar parents using proton magnetic resonance spectroscopy. European Child and Adolescent Psychiatry, 2021, 30, 55-64.	4.7	16
27	A commentary on youth onset bipolar disorder. Bipolar Disorders, 2021, 23, 834-837.	1.9	6
28	Effectiveness of Mindfulness-Based Cognitive Therapy–Child With Youth Who Have a Parent Diagnosed With Bipolar I Disorder. Journal of Mental Health Counseling, 2021, 43, 59-74.	0.9	0
29	Mindfulnessâ€based cognitive therapy for children and adolescents with anxiety disorders atâ€risk for bipolar disorder: A psychoeducation waitlist controlled pilot trial. Microbial Biotechnology, 2020, 14, 211-219.	1.7	23
30	Identifying epilepsy psychiatric comorbidities with machine learning. Acta Neurologica Scandinavica, 2020, 141, 388-396.	2.1	15
31	Metabolic Monitoring Rates of Youth Treated with Second-Generation Antipsychotics in Usual Care: Results of a Large US National Commercial Health Plan. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 119-122.	1.3	15
32	Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 267-272.	1.3	4
33	Greater Dynamic and Lower Static Functional Brain Connectivity Prospectively Predict Placebo Response in Pediatric Generalized Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 606-616.	1.3	3
34	Isn't the evidence base for pediatric bipolar disorder already sufficient to inform clinical practice?. Bipolar Disorders, 2020, 22, 664-665.	1.9	5
35	Frontolimbic brain volume abnormalities in bipolar disorder with suicide attempts. Psychiatry Research, 2020, 294, 113516.	3.3	5
36	Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders. Neuropsychopharmacology, 2020, 45, 1369-1379.	5.4	25

#	Article	IF	CITATIONS
37	The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Perspectives. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 376-380.	1.3	16
38	A Machine Learning Approach to Identifying Changes in Suicidal Language. Suicide and Life-Threatening Behavior, 2020, 50, 939-947.	1.9	16
39	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	4.1	18
40	Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 293-305.	1.3	11
41	A Preliminary Study of the Effects of Treatment with Lithium Versus Quetiapine on Attention of Adolescents with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 465-469.	1.3	5
42	159 Safety and Efficacy of Lurasidone in Children and Adolescents with Bipolar Depression: Results from a 2-Year Open-label Extension Study. CNS Spectrums, 2020, 25, 301-302.	1.2	1
43	Medication exposure and predictors of first mood episode in offspring of parents with bipolar disorder: a prospective study. Revista Brasileira De Psiquiatria, 2020, 42, 481-488.	1.7	10
44	Escitalopram in Adolescents With Generalized Anxiety Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	48
45	Capacity to provide informed consent among adults with bipolar disorder. Journal of Affective Disorders, 2019, 242, 1-4.	4.1	2
46	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.9	71
47	Neurophysiological effects of multiple mood episodes in bipolar disorder. Bipolar Disorders, 2019, 21, 503-513.	1.9	27
48	Clinical Conundrum: How do you treat youth with depression and a family history of bipolar disorder?. Bipolar Disorders, 2019, 21, 383-386.	1.9	6
49	Longitudinal proton spectroscopy study of the prefrontal cortex in youth at risk for bipolar disorder before and after their first mood episode. Bipolar Disorders, 2019, 21, 330-341.	1.9	15
50	Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. Psychiatry Research - Neuroimaging, 2019, 286, 53-59.	1.8	24
51	Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 287-296.e4.	0.5	32
52	Essential Pharmacotherapies for Bipolar Disorder. Current Treatment Options in Psychiatry, 2019, 6, 75-97.	1.9	0
53	Thyroid Function Screening in Children and Adolescents With Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2019, 80, .	2.2	6
54	Treating Bipolar Disorder in Pediatric Patients and Educating Patients and Parents. Journal of Clinical Psychiatry, 2019, 80, .	2.2	1

#	Article	IF	CITATIONS
55	Factor analysis of regional brain activation in bipolar and healthy individuals reveals a consistent modular structure. Journal of Affective Disorders, 2018, 234, 14-19.	4.1	10
56	Cardiometabolic risks and omegaâ€3 index in recentâ€onset bipolar I disorder. Bipolar Disorders, 2018, 20, 658-665.	1.9	11
57	Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. Current Problems in Pediatric and Adolescent Health Care, 2018, 48, 50-62.	1.7	67
58	Clinical Relevance Versus Statistical Significance: DelBello and Colleagues Respond to Editorial. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 353-354.	0.5	0
59	MRI Evidence of Neuropathic Changes in Former College Football Players. Clinical Journal of Sport Medicine, 2018, 28, 100-105.	1.8	27
60	A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 47-54.	1.3	12
61	Bipolar Disorder in Primary Care: Considerations in Management. Current Treatment Options in Psychiatry, 2018, 5, 441-451.	1.9	0
62	Mobility for All?. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 792-793.	0.5	0
63	A Risk Calculator for Bipolar Disorder in Youth: Improving the Odds for Personalized Prevention and Early Intervention?. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 725-727.	0.5	8
64	Discrete patterns of cortical thickness in youth with bipolar disorder differentially predict treatment response to quetiapine but not lithium. Neuropsychopharmacology, 2018, 43, 2256-2263.	5.4	38
65	Prediction of lithium response in firstâ€episode mania using the LITHium Intelligent Agent ( <scp>LITHIA</scp> ): Pilot data and proofâ€ofâ€concept. Bipolar Disorders, 2017, 19, 259-272.	1.9	59
66	Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 526-534.	1.3	13
67	White matter volumes in youth offspring of bipolar parents. Journal of Affective Disorders, 2017, 209, 246-253.	4.1	22
68	The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disorders, 2017, 19, 524-543.	1.9	152
69	Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 1015-1025.	0.5	79
70	A Pharmacologic Algorithm for Youth Who Are at High Risk for Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 796-805.	1.3	23
71	Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination. Child and Adolescent Psychiatry and Mental Health, 2017, 11, 34.	2.5	10
72	Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. Journal of Clinical Psychiatry, 2017, 78, e1158-e1166.	2.2	6

#	Article	IF	CITATIONS
73	The Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder: Signal detection and validation. Annals of Clinical Psychiatry, 2017, 29, 227-234A.	0.6	107
74	Mindfulnessâ€based cognitive therapy for youth with anxiety disorders at risk for bipolar disorder: a pilot trial. Microbial Biotechnology, 2016, 10, 426-434.	1.7	63
75	Adolescents with or at ultraâ€high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker. Microbial Biotechnology, 2016, 10, 203-211.	1.7	42
76	Familial risk for bipolar disorder is not associated with impaired peroxisomal function: Dissociation from docosahexaenoic acid deficits. Psychiatry Research, 2016, 246, 803-807.	3.3	7
77	Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 490-491.	1.3	8
78	Neurofunctional Differences Among Youth With and at Varying Risk for Developing Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 980-989.	0.5	15
79	A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 922-934.	1.3	16
80	fMRI brain activation changes following treatment of a first bipolar manic episode. Bipolar Disorders, 2016, 18, 490-501.	1.9	48
81	Neural Function Before and After Mindfulness-Based Cognitive Therapy in Anxious Adolescents at Risk for Developing Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 372-379.	1.3	73
82	Tissue-dependent cerebral energy metabolism in adolescents with bipolar disorder. Journal of Affective Disorders, 2016, 191, 248-255.	4.1	38
83	Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder. Journal of Affective Disorders, 2016, 192, 176-183.	4.1	39
84	Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: A preliminary 1H MRS study. Nutritional Neuroscience, 2016, 19, 145-155.	3.1	11
85	Neurofunctional effects of quetiapine in patients with bipolar mania. Bipolar Disorders, 2015, 17, 444-449.	1.9	8
86	First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine. Psychiatry Research, 2015, 230, 447-453.	3.3	22
87	Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 217-224.	0.5	62
88	Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study. Pediatrics, 2015, 136, 885-894.	2.1	82
89	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. European Child and Adolescent Psychiatry, 2015, 24, 1485-1496.	4.7	18
90	Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1020-1031.e3.	0.5	37

#	Article	IF	CITATIONS
91	Neurostructural impact of co-occurring anxiety in pediatric patients with major depressive disorder: A voxel-based morphometry study. Journal of Affective Disorders, 2015, 171, 54-59.	4.1	27
92	Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study. Bipolar Disorders, 2014, 16, 523-530.	1.9	59
93	A Double-Blind, Placebo-Controlled Study of Selegiline Transdermal System in Depressed Adolescents. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 311-317.	1.3	25
94	Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 771-779.	0.5	16
95	The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder. Psychiatry Research - Neuroimaging, 2014, 223, 268-270.	1.8	15
96	Hospitalized youth and child abuse: A systematic examination of psychiatric morbidity and clinical severity. Child Abuse and Neglect, 2014, 38, 76-83.	2.6	31
97	Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 325-335.	1.3	65
98	Cortical surface anatomy in pediatric patients with generalized anxiety disorder. Journal of Anxiety Disorders, 2014, 28, 717-723.	3.2	45
99	Correlations of inflammatory gene pathways, corticolimbic functional activities, and aggression in pediatric bipolar disorder: A preliminary study. Psychiatry Research - Neuroimaging, 2014, 224, 107-111.	1.8	21
100	Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder. PharmaNutrition, 2014, 2, 38-46.	1.7	61
101	Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I Disorder. Journal of Clinical Psychiatry, 2013, 74, e100-e109.	2.2	64
102	Functional Magnetic Resonance Imaging Brain Activation in Bipolar Mania: Evidence for Disruption of the Ventrolateral Prefrontal-Amygdala Emotional Pathway. Biological Psychiatry, 2011, 69, 381-388.	1.3	128
103	Retrospective age at onset of bipolar disorder and outcome during twoâ€year followâ€up: results from the STEPâ€BD study. Bipolar Disorders, 2009, 11, 391-400.	1.9	229
104	A doubleâ€blind, placeboâ€controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disorders, 2009, 11, 483-493.	1.9	117
105	Neuroanatomical Characterization of Child Offspring of Bipolar Parents. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 526-531.	0.5	59
106	Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 491-499.	1.3	47
107	Twelve-Month Outcome of Adolescents With Bipolar Disorder Following First Hospitalization for a Manic or Mixed Episode. American Journal of Psychiatry, 2007, 164, 582-590.	7.2	269
108	Response and Remission in Adolescent Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 628-635.	0.5	23

#	Article	IF	CITATIONS
109	ACUTE DYSTONIA ASSOCIATED WITH ARIPIPRAZOLE IN A CHILD. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 306-307.	0.5	15
110	Reply to Drs. Fossey, Allen and Yates regarding â€~Concurrent tracking of alcohol use and bipolar disorder symptoms'. Bipolar Disorders, 2007, 9, 790-791.	1.9	0
111	A 12-Week Single-Blind Trial of Quetiapine for the Treatment of Mood Symptoms in Adolescents at High Risk for Developing Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 789-795.	2.2	90
112	Lithium Treatment Effects on Myo-Inositol in Adolescents with Bipolar Depression. Biological Psychiatry, 2006, 60, 998-1004.	1.3	51
113	A Double-Blind Randomized Pilot Study Comparing Quetiapine and Divalproex for Adolescent Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 305-313.	0.5	186
114	Open-Label Lithium for the Treatment of Adolescents With Bipolar Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 289-297.	0.5	102
115	Pharmacological interventions for bipolar youth: Developmental considerations. Development and Psychopathology, 2006, 18, 1231-46.	2.3	20
116	The Neurophysiology of Childhood and Adolescent Bipolar Disorder. CNS Spectrums, 2006, 11, 298-311.	1.2	50
117	Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disorders, 2006, 8, 710-720.	1.9	132
118	Neurochemical Effects of Olanzapine in First-Hospitalization Manic Adolescents: A Proton Magnetic Resonance Spectroscopy Study. Neuropsychopharmacology, 2006, 31, 1264-1273.	5.4	119
119	A Pilot Controlled Trial of Topiramate for Mania in Children and Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 539-547.	0.5	133
120	Prevalence and the Shift in Age of Onset. CNS Spectrums, 2004, 9, 12-18.	1.2	0
121	Parametric neurocognitive task design: a pilot study of sustained attention in adolescents with bipolar disorder. Journal of Affective Disorders, 2004, 82, S79-S88.	4.1	28
122	Neurochemical predictors of response to pharmacologic treatments for bipolar disorder. Current Psychiatry Reports, 2004, 6, 466-472.	4.5	20
123	Magnetic resonance imaging analysis of amygdala and other subcortical brain regions in adolescents with bipolar disorder. Bipolar Disorders, 2004, 6, 43-52.	1.9	324
124	Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry, 2004, 55, 875-881.	1.3	746
125	Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. Journal of Clinical Psychiatry, 2004, 65 Suppl 6, 12-9.	2.2	3
126	Rates and Predictors of Developing a Manic or Hypomanic Episode 1 to 2 Years Following a First Hospitalization for Major Depression with Psychotic Features. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 173-185.	1.3	39

#	Article	IF	CITATIONS
127	Adjunctive Topiramate Treatment for Pediatric Bipolar Disorder: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2002, 12, 323-330.	1.3	78
128	A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 1216-1223.	0.5	375
129	Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) Mania and Rapid Cycling Sections. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 450-455.	0.5	379
130	Comparative Efficacy and Tolerability of Drug Treatments for Bipolar Disorder. CNS Drugs, 2001, 15, 701-718.	5.9	47
131	Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disorders, 2001, 3, 53-57.	1.9	170
132	Review of studies of child and adolescent offspring of bipolar parents. Bipolar Disorders, 2001, 3, 325-334.	1.9	258
133	Human Response to Repeated Low-Dose d-Amphetamine: Evidence for Behavioral Enhancement and Tolerance. Neuropsychopharmacology, 2001, 25, 548-554.	5.4	63
134	Effects of Race on Psychiatric Diagnosis of Hospitalized Adolescents: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2001, 11, 95-103.	1.3	81
135	Neuroimaging in bipolar disorder. Bipolar Disorders, 2000, 2, 148-164.	1.9	242
136	MRI Analysis of the Cerebellum in Bipolar Disorder A Pilot Study. Neuropsychopharmacology, 1999, 21, 63-68.	5.4	222